Dai ichi Life Insurance Company Ltd Sells 2,383 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Dai ichi Life Insurance Company Ltd lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 16.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 12,392 shares of the biopharmaceutical company's stock after selling 2,383 shares during the period. Dai ichi Life Insurance Company Ltd's holdings in Regeneron Pharmaceuticals were worth $13,027,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in REGN. International Assets Investment Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 86,013.3% in the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company's stock worth $926,078,000 after purchasing an additional 879,916 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Regeneron Pharmaceuticals by 1.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company's stock valued at $707,759,000 after acquiring an additional 11,499 shares during the last quarter. Massachusetts Financial Services Co. MA increased its position in shares of Regeneron Pharmaceuticals by 12.4% during the second quarter. Massachusetts Financial Services Co. MA now owns 540,293 shares of the biopharmaceutical company's stock valued at $567,864,000 after acquiring an additional 59,769 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in shares of Regeneron Pharmaceuticals by 23.8% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,274 shares of the biopharmaceutical company's stock valued at $525,804,000 after acquiring an additional 96,266 shares during the last quarter. Finally, TD Asset Management Inc increased its position in shares of Regeneron Pharmaceuticals by 30.4% during the second quarter. TD Asset Management Inc now owns 351,545 shares of the biopharmaceutical company's stock valued at $369,484,000 after acquiring an additional 82,034 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Truist Financial decreased their price target on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a "buy" rating for the company in a research report on Friday, November 1st. Morgan Stanley decreased their price target on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an "overweight" rating for the company in a research report on Friday, November 1st. Wolfe Research initiated coverage on Regeneron Pharmaceuticals in a research report on Friday, November 15th. They set an "outperform" rating and a $1,150.00 price target for the company. Oppenheimer decreased their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an "outperform" rating for the company in a research report on Wednesday, November 6th. Finally, Wells Fargo & Company decreased their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an "overweight" rating for the company in a research report on Tuesday, October 22nd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $1,099.55.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN traded down $0.82 during trading hours on Tuesday, hitting $748.69. 416,066 shares of the company's stock traded hands, compared to its average volume of 541,591. The firm has a market cap of $82.27 billion, a P/E ratio of 18.55, a P/E/G ratio of 2.84 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a 52 week low of $735.95 and a 52 week high of $1,211.20. The business's fifty day simple moving average is $937.00 and its two-hundred day simple moving average is $1,025.99. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the firm's stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. This trade represents a 27.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 7.48% of the stock is owned by corporate insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.